Literature DB >> 20530450

Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters.

Klaus Bodner1, Peter Laubichler, Oliver Kimberger, Klaus Czerwenka, Robert Zeillinger, Barbara Bodner-Adler.   

Abstract

OBJECTIVE: The expression of oestrogen and progesterone receptors in patients with adenocarcinoma of the uterine cervix was examined in order to determine their influence on prognosis and to evaluate the association between the steroid receptor expression and various clinicopathologic parameters. PATIENTS AND METHODS: Oestrogen and progesterone receptor expression was investigated by immunohistochemistry from paraffin-embedded tissue in 39 patients with adenocarcinoma of the uterine cervix. The immunohistochemical findings were correlated with various clinicopathological parameters of the patients.
RESULTS: Oestrogen and progesterone receptors were expressed in 39% and 33% of the patients, respectively. The relationship between oestrogen and progesterone receptor expression and clinical stage, age, histology, tumour size, grade, lymph-vascular space invasion and lymph node status did not reach statistical significance (p>0.05). Neither oestrogen nor progesterone receptor expression significantly influenced disease-free and overall survival (p>0.05).
CONCLUSION: Oestrogen and progesterone receptors were frequently expressed in adenocarcinoma of the uterine cervix. However, their expression did not correlate with clinicopathological parameters and had no influence on overall and disease-free survival. Thus, the investigation of steroid receptors adds little additional information to the clinical management and fails to play a prognostic role in cervical adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20530450

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

Review 1.  [Diagnosis and differential diagnosis of cervical adenocarcinoma].

Authors:  T Löning; L Riethdorf; M Köbel
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

Review 2.  Role of nuclear progesterone receptor isoforms in uterine pathophysiology.

Authors:  Bansari Patel; Sonia Elguero; Suruchi Thakore; Wissam Dahoud; Mohamed Bedaiwy; Sam Mesiano
Journal:  Hum Reprod Update       Date:  2014-11-18       Impact factor: 15.610

3.  Elevated expression of G protein-coupled receptor 30 (GPR30) is associated with poor prognosis in patients with uterine cervical adenocarcinoma.

Authors:  Yoshihiko Ino; Taishi Akimoto; Akira Takasawa; Kumi Takasawa; Tomoyuki Aoyama; Asako Ueda; Misaki Ota; Kazufumi Magara; Yohei Tagami; Masaki Murata; Tadashi Hasegawa; Tsuyoshi Saito; Norimasa Sawada; Makoto Osanai
Journal:  Histol Histopathol       Date:  2019-09-04       Impact factor: 2.303

4.  The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer.

Authors:  Klaus Friese; Bernd Kost; Aurelia Vattai; Frederik Marmé; Christina Kuhn; Sven Mahner; Christian Dannecker; Udo Jeschke; Sabine Heublein
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-18       Impact factor: 4.553

Review 5.  Using menopausal hormone therapy after a cancer diagnosis in Ireland.

Authors:  Fionán Donohoe; Yvonne O'Meara; Aidin Roberts; Louise Comerford; Catherine M Kelly; Janice M Walshe; Deirdre Lundy; Martha Hickey; Donal J Brennan
Journal:  Ir J Med Sci       Date:  2022-02-09       Impact factor: 1.568

6.  SERMs suppresses the growth of ERα positive cervical cancer xenografts through predominant inhibition of extra-nuclear ERα expression.

Authors:  Balaji Ramachandran; Kanchan Murhekar; Shirley Sundersingh
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

7.  Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy.

Authors:  Philip Carter; Costi Alifrangis; Biancastella Cereser; Pramodh Chandrasinghe; Lisa Del Bel Belluz; Christina Fotopoulou; Andreja Frilling; Thomas Herzog; Nina Moderau; Neha Tabassum; Jonathan Krell; Justin Stebbing
Journal:  Oncotarget       Date:  2017-12-27

8.  Expression of Estrogen and Progesterone Receptor in Tumor Stroma Predicts Favorable Prognosis of Cervical Squamous Cell Carcinoma.

Authors:  Mun-Kun Hong; Jen-Hung Wang; Cheng-Chuan Su; Ming-Hsun Li; Yung-Hsiang Hsu; Tang-Yuan Chu
Journal:  Int J Gynecol Cancer       Date:  2017-07       Impact factor: 3.437

9.  Estrogen/GPR30 Signaling Contributes to the Malignant Potentials of ER-Negative Cervical Adenocarcinoma via Regulation of Claudin-1 Expression.

Authors:  Taishi Akimoto; Akira Takasawa; Kumi Takasawa; Tomoyuki Aoyama; Masaki Murata; Makoto Osanai; Tsuyoshi Saito; Norimasa Sawada
Journal:  Neoplasia       Date:  2018-09-15       Impact factor: 5.715

10.  Effect of tibolone on the survival of early stage cervical adenocarcinoma patients.

Authors:  Seung-Ho Lee; Yoon-Jin Cho; Kyung-Joo Cho; Mee-Hyang Ko; Sun-Young Jung; Seung-Joo Chon; So-Yi Lim; Kwang-Beom Lee
Journal:  Obstet Gynecol Sci       Date:  2018-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.